A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer

Investigational New Drugs

Volumn 29, Issue 4, 2011, Pages 694-699

  El Rayes, Bassel Fuad ^a,c   Philip, Philip A ^a   Sarkar, Fazlul H ^a   Shields, Anthony F ^a   Ferris, Ann Marie ^a   Hess, Kenneth ^b   Kaseb, Ahmad O ^b   Javle, Milind M ^b   Varadhachary, Gauri R ^b   Wolff, Robert A ^b   Abbruzzese, James L ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Erlotinib; Gemcitabine; Genistein; Isoflavone; Pancreatic cancer

Indexed keywords

ERLOTINIB; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOFLAVONE DERIVATIVE; NOVASOY; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELLULITIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFECTION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOFLAVONES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; NF-KAPPA B; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES;

EID: 79959327460     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9386-6     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71-96 (Pubitemid 351521864)
2. El-Rayes BF, Philip PA (2002) Systemic therapy for advanced pancreatic cancer. Expert Rev Anticancer Ther 2(4):426-436 (Pubitemid 34947119)
3. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15):1960-1966 (Pubitemid 46972777)
4. Philip PA, Benedetti J, Fenoglio-Preiser C, Zalupski M, Lenz H, O'Reilly E et al (2007) Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. ASCO Annual Meeting Proceedings Part I, Chicago, Il. J Clin Oncol 25 (18S, June 20 Supplement): Abstract number LBA4509
5. Vanhaesebroeck B, Alessi DR (2000) The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 346(Pt 3):561-576 (Pubitemid 30171014)
6. Downward J (1998) Signal transduction. New exchange, new target. Nature 396(6710):416-417
7. Jones DR, Broad RM, Madrid LV, Baldwin AS Jr, Mayo MW (2000) Inhibition of NF-kappaB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis. Ann Thorac Surg 70(3):930-936, discussion 6-7
8. Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S et al (2000) Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 19(36):4159-4169
9. Ng SSW, Tsao MS, Chow S, Hedley DW (2000) Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 60 (19):5451-5455
10. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ (1999) The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5(1):119-127 (Pubitemid 29045184)
11. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK et al (1996) Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 93(8):3636-3641 (Pubitemid 26127592)
12. Li Y, Sarkar FH (2002) Gene expression profiles of genistein-treated PC3 prostate cancer cells. J Nutr 132(12):3623-3631 (Pubitemid 35435038)
13. Li Y, Sarkar FH (2002) Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein. Cancer Lett 186(2):157-164 (Pubitemid 35246201)
14. Alhasan SA, Aranha O, Sarkar FH (2001) Genistein elicits pleiotropic molecular effects on head and neck cancer cells. Clin Cancer Res 7(12):4174-4181 (Pubitemid 34044643)
15. Li Y, Sarkar FH (2002) Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res 8(7):2369-2377 (Pubitemid 34753612)
16. Sarkar FH, Li Y (2002) Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev 21(3-4):265-280 (Pubitemid 36071914)
17. Li Y, Ellis KL, Ali S, El-Rayes BF, Nedeljkovic-Kurepa A, Kucuk O et al (2004) Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. Pancreas 28(4):e90-e95
18. Ali S, Banerjee S, Ahmad A, El-Rayes BF, Philip PA, Sarkar FH (2008) Apoptosis-inducing effect of erlotinib is potentiated by 3,3′- diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Cancer Ther 7(6):1708-1719
19. Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ et al (2005) Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 65(19):9064-9072 (Pubitemid 41377399)
20. El-Rayes BF, Ali S, Ali IF, Philip PA, Abbruzzese J, Sarkar FH (2006) Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer Res 66(21):10553-10559 (Pubitemid 44799778)
21. Hussain M, Banerjee M, Sarkar FH, Djuric Z, Pollak MN, Doerge D et al (2003) Soy isoflavones in the treatment of prostate cancer. Nutr Cancer 47(2):111-117 (Pubitemid 38590881)
22. Davis JN, Kucuk O, Djuric Z, Sarkar FH (2001) Soy isoflavone supplementation in healthy men prevents NF-kappa B activation by TNF-alpha in blood lymphocytes. Free Radic Biol Med 30(11):1293-1302 (Pubitemid 32463940)
23. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
24. Li Y, Ross-Viola JS, Shay NF, Moore DD, Ricketts ML (2009) Human CYP3A4 and murine Cyp3A11 are regulated by equol and genistein via the pregnane X receptor in a species-specific manner. J Nutr 139(5):898-904
25. Lu JF, Eppler SM, Wolf J, Hamilton M, Rakhit A, Bruno R et al (2006) Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 80(2):136-145 (Pubitemid 44160689)
26. Cassileth BR, Deng G (2004) Complementary and alternative therapies for cancer. The Oncologist 9(1):80-89 (Pubitemid 38134016)